Cellectar Biosciences Inc
Company Profile
Business description
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
Contact
100 Campus Drive
Florham ParkNJ07932
USAT: +1 608 441-8120
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
11
Stocks News & Analysis
stocks
ASX top pick remains cheap despite weaker consumer confidence
stocks
Chart of the Week: Aussie dividend yields below 10-year average
stocks
Apple earnings: A smooth transition despite continued memory and supply headwinds
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,205.20 | 250.30 | 2.80% |
| CAC 40 | 8,205.37 | 27.48 | 0.34% |
| DAX 40 | 26,325.01 | 112.66 | -0.43% |
| Dow JONES (US) | 51,523.06 | 1,833.06 | -3.44% |
| FTSE 100 | 10,782.66 | 46.55 | -0.43% |
| HKSE | 24,796.98 | 877.48 | 3.67% |
| NASDAQ | 24,315.00 | 1,421.52 | -5.52% |
| Nikkei 225 | 61,077.90 | 1,110.73 | -1.79% |
| NZX 50 Index | 13,903.63 | 187.34 | -1.33% |
| S&P 500 | 7,353.73 | 334.89 | -4.36% |
| S&P/ASX 200 | 9,065.10 | 230.60 | 2.61% |
| SSE Composite Index | 3,689.91 | 3.74 | 0.10% |